<DOC>
	<DOCNO>NCT02346201</DOCNO>
	<brief_summary>Apathy Dementia Methylphenidate Trial 2 ( ADMET 2 ) Phase III , placebo-controlled , mask , 6 month , 10-center randomized clinical trial sponsor National Institutes Aging involve 200 participant Alzheimer 's disease ( AD ) . ADMET 2 design examine efficacy safety methylphenidate treatment clinically significant apathy AD participant . ADMET 2 enroll participant real world setting outpatient , nursing home , assist living facility examine effect methylphenidate apathy cognition . ADMET 2 also conduct careful safety monitoring .</brief_summary>
	<brief_title>Apathy Dementia Methylphenidate Trial 2</brief_title>
	<detailed_description>ADMET 2 examine mask , randomize trial efficacy methylphenidate treatment clinically significant apathy participant Alzheimer 's dementia . Efficacy assess change Neuropsychiatric Inventory Apathy subscale ( NPI apathy ) baseline 6 month score Alzheimer 's Disease Cooperative Study - Clinical Global Impression Change ( CGIC ) scale 6 month . ADMET 2 also examine safety methylphenidate treatment clinically significant apathy participant Alzheimer 's disease measure vital sign , electrolyte panel , adverse event report , electrocardiogram . Safety also measure examine neuropsychiatric symptom apathy use Neuropsychiatric Inventory ( NPI ) . Changes baseline 6 month neuropsychological assessment measure use Dementia Apathy Interview Rating ( DAIR ) scale also assess . Cost-effectiveness measure assess quality life economic assessment cognitive change use cognitive battery include Mini Mental State Exam ( MMSE ) scale .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Inclusion criterion Possible probable Alzheimer 's disease ( National Institute Neurological Communicative Disorders Stroke Alzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) criterion ) , MiniMental State Exam ( MMSE ) score 1028 inclusive Clinically significant apathy least four week either frequency apathy assess Neuropsychiatric Inventory ( NPI ) 'Very frequently ' , frequency apathy assess NPI 'Frequently ' 'Often ' AND severity apathy assess NPI 'Moderate ' 'Marked ' A medication apathy appropriate , opinion study physician Provision inform consent participation study potential participant surrogate ( participant assent potential participant unable provide inform consent ) caregiver Availability primary caregiver , spend great ten hour week potential participant supervise his/her care , accompany potential participant study visit participate study Sufficient fluency , potential participant caregiver , write spoken English participate study visit , physical exam , outcome assessment If female , woman must postmenopausal least 2 year hysterectomy Exclusion criterion Currently meet criterion Major Depressive Episode , Diagnostic Statistical Manual Mental Disorder IV ( TR ) criteria Clinically significant agitation /aggression either frequency agitation /aggression assess NPI 'Very frequently ' , frequency agitation /aggression assess NPI 'Frequently ' AND severity agitation assess NPI 'Moderate ' , 'Marked ' Clinically significant delusion either frequency delusion assess NPI 'Very frequently ' , frequency delusion assess NPI 'Frequently ' AND severity delusion assess NPI 'Moderate ' , 'Marked ' Clinically significant hallucination either frequency hallucination assess NPI 'Very frequently ' , frequency hallucination assess NPI 'Frequently ' AND severity hallucination assess NPI 'Moderate ' , 'Marked ' Change AD medication within month precede randomization , include start , stop , dosage modification Change antidepressant ( except trazodone use sleep difficulty describe ) use within 30 day precede randomization period time equal 5 halflives drug , whichever period time longer Use trazodone &gt; 50mg lorazepam &gt; 0.5mg indication sleep difficulty within 30 day precede randomization period time equal 5 halflives drug , whichever period time longer . Other benzodiazepine prohibit past 30 day within 5 halflives , whichever period time longer . Failure treatment methylphenidate past apathy convince evidence adequate trial judge study physician Currently take amphetamine product , antipsychotic , bupropion , medication would prohibit safe concurrent use methylphenidate , include limited monoamine oxidase inhibitor tricyclic antidepressant within 30 day precede randomization period time equal 5 halflives drug , whichever period time longer Need acute psychiatric hospitalization suicidal opinion study physician Significant communicative impairment would affect participation clinical trial Central nervous system abnormality ( e.g. , cerebral aneurysm ) , seizure ( convulsion , epilepsy ) , Tourette 's syndrome presence motor tic , abnormal electroencephalogram Lack appetite result significant unintentional weight loss determine study physician last three month Uncontrolled hyperthyroidism Any cardiovascular cerebrovascular abnormality deem clinically significant study physician , tachycardia ( heart rate &gt; 100 beat per minute ) , uncontrolled hypertension ( defined medication noncompliance past 3 month diastolic read &gt; 105 mm Hg ) , time screen Closed angle glaucoma pheochromocytoma Women childbearing potential Current participation clinical trial study may add significant burden affect study outcomes Any condition , opinion study physician , make medically inappropriate risky potential participant enroll trial , include , limited , contraindication treatment methylphenidate .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>